Advisory Board | Algernon NeuroScience

Dr. Martin Kolb

focchino@mkpdigital.ca — Thu, 19 Dec 2019 18:44:58 +0000

Dr. Kolb is the Moran Campbell Chair and Professor in Respiratory Medicine and Director of the Division of Respirology, McMaster University, Hamilton, Ontario, Canada. He is lead of the interstitial lung disease program, located at St. Joseph’s Healthcare Hamilton, where more than 1,500 patients with different types of fibrotic interstitial lung disorders are seen annually. His major research interests are the mechanisms of lung fibrosis, with a particular interest in the role of growth factors, matrix abnormalities and pulmonary vessel remodeling in disease progression.

He leads activities in biomarker development for lung fibrosis, and is a Principal Investigator and steering committee member in numerous clinical trials. Dr. Kolb has authored over 150 peer-reviewed publications on different basic science and clinical topics. He is the Chief-Editor of the European Respiratory Journal, the flagship publication of the European Respiratory Society. He is also an editorial board member of American Journal of Respiratory and Critical Care Medicine, American Journal of Respiratory Cell and Molecular Biology, the European Respiratory Review and Respirology and serves on the Lung Injury & Repair Study Section for the National Institute of Health.

Dr. Walter Reinisch

focchino@mkpdigital.ca — Thu, 19 Dec 2019 18:43:58 +0000

Dr. Walter Reinisch, MD, is a leading global scientific expert and clinician in the area of IBD has joined the Algernon Medical and Scientific Advisory Board. Dr. Reinisch is a founding member of the European Crohn’s & Colitis Organization and was assigned as an honorary member after having contributed in various positions. He was active in the Scientific and Public Affairs Committee of the United European Gastroenterology and headed the Austrian IBD Study Group. Dr. Reinisch is a member of the International Organization For the Study of Inflammatory Bowel Disease.

Dr. Reinisch is an expert in designing, conducting and interpreting the results of clinical trials in IBD. He envisions a customized management of IBD utilizing the innovations of translational medicine. He advocates the implementation of a “common language of inflammatory bowel disease” to improve the communication with patients and between physicians for a better care and more robust research outcomes. Dr. Reinisch has also either written or made contributions to over 250 publications on IBD and remains active in all aspects of IBD research.

Dr. Arun Sanyal

focchino@mkpdigital.ca — Thu, 19 Dec 2019 18:43:03 +0000

Dr. Arun Sanyal, MD, is a leading global expert and clinician in the area of chronic liver disease. Dr. Sanyal has developed, mediated and encouraged global liver research as a physician-scientist for 25 years. Currently, Dr. Sanyal is the Vlahcevic Chair of Medicine in the department of Internal Medicine at Virginia Commonwealth University (VCU) and Director of the KL2 program in the Center for Clinical and Translational Research at VCU.

Dr. Sanyal’s medical career has spanned the spectrum of translational science in liver cirrhosis, NASH and non-alcoholic fatty liver disease (NAFLD), with a particular focus on obesity and cardiovascular effects related to liver disease. Dr. Sanyal is a Past President of the AASLD (American Association for the Study of Liver Diseases), and has chaired committees at the NIDDK NASH clinical research network and the NIH hepatobiliary study section. He recently received the 2018 Distinguished Achievement Award from the American Association for the Study of Liver Diseases. The award signifies 30 years of research including 17 continuous years of National Institutes of Health funding, the development of therapeutics reducing liver disease across the globe, and countless international leadership roles and awards.